These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35945426)

  • 1. The India Hypertension Control Initiative-early outcomes in 26 districts across five states of India, 2018-2020.
    Kaur P; Kunwar A; Sharma M; Durgad K; Gupta S; ; Bhargava B
    J Hum Hypertens; 2023 Jul; 37(7):560-567. PubMed ID: 35945426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. India Hypertension Control Initiative: Blood Pressure Control Using Drug and Dose-Specific Standard Treatment Protocol at Scale in Punjab and Maharashtra, India, 2022.
    Kaur P; Sakthivel M; Venkatasamy V; Jogewar P; Gill SS; Kunwar A; Sharma M; Pathni AK; Durgad K; Sahoo SK; Wankhede A; Kumar N; Bharadwaj V; Das B; Chavan T; Khedkar S; Sarode L; Bangar SD; Krishna A; Shivashankar R; Ganeshkumar P; Pragya P; Bhargava B
    Glob Heart; 2024; 19(1):30. PubMed ID: 38524909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the availability of antihypertensive drugs in the India Hypertension Control Initiative, India, 2019-2020.
    Kunwar A; Kaur P; Durgad K; Parasuraman G; Sharma M; Gupta S; Bhargava B;
    PLoS One; 2023; 18(12):e0295338. PubMed ID: 38096180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions to Ensure the Continuum of Care for Hypertension During the COVID-19 Pandemic in Five Indian States-India Hypertension Control Initiative.
    Kunwar A; Durgad K; Kaur P; Sharma M; Swasticharan L; Mallela M; Saxena A; Tayade S; Gill S; Gopal BK; Pathni AK; Tullu FT; Dhaliwal RS; Bhargava B
    Glob Heart; 2021; 16(1):82. PubMed ID: 34909373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. India Hypertension Control Initiative-Hypertension treatment and blood pressure control in a cohort in 24 sentinel site clinics.
    Kaur P; Kunwar A; Sharma M; Mitra J; Das C; Swasticharan L; Chakma T; Dipak Bangar S; Venkatasamy V; Dharamsoth R; Purohit S; Tayade S; Singh GB; Bitragunta S; Durgad K; Das B; Dar S; Bharadwaj R; Joshi C; Bharadwaj V; Khedkar S; Chenji S; Reddy SK; Sreedhar C; Parasuraman G; Kasiviswanathan S; Viswanathan V; Uike P; Gaigaware P; Yadav S; Dhaliwal RS; Ramakrishnan S; Tullu FT; Bhargava B
    J Clin Hypertens (Greenwich); 2021 Apr; 23(4):720-729. PubMed ID: 33369074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide.
    Ando K; Isshiki M; Takahashi K;
    Hypertens Res; 2009 Sep; 32(9):748-52. PubMed ID: 19590506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research Letter: Antihypertensive Drugs Market in India: An Insight on Size, Trends, and Prescribing Preferences in the Private Health Sector, 2016-2018.
    Sahoo SK; Pathni AK; Krishna A; Moran AE; Cohn J; Bhatia S; Maheshwari N; Sharma B
    Glob Heart; 2021; 16(1):51. PubMed ID: 34381673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perspective of private health care providers in the state of Madhya Pradesh on adopting key strategies of the India hypertension control initiative.
    Krishna A; Pathni AK; Sharma B; Shivashankar R; Shrivastava S; Hering D
    J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1321-1327. PubMed ID: 33289944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
    Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
    N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
    Chaugai S; Sherpa LY; Sepehry AA; Kerman SRJ; Arima H
    J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):433-445. PubMed ID: 29739234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.
    Destro M; Cagnoni F; D'Ospina A; Ricci AR; Demichele E; Peros E; Zaninelli A; Preti P
    Vasc Health Risk Manag; 2010 Apr; 6():253-60. PubMed ID: 20407632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
    Tocci G; Paneni F; Passerini J; Volpe M
    Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating essential hypertension. The first choice is usually a thiazide diuretic.
    Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.
    Hwang AY; Dave C; Smith SM
    Hypertension; 2016 Dec; 68(6):1349-1354. PubMed ID: 27777360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial.
    Ojji DB; Cornelius V; Partington G; Francis V; Pandie S; Smythe W; Hickman N; Barasa F; Damasceno A; Dzudie A; Jones E; Ingabire PM; Mondo C; Ogah O; Ogola E; Sani MU; Shedul GL; Shedul G; Rayner B; Sliwa K; Poulter N;
    Hypertension; 2022 Nov; 79(11):2593-2600. PubMed ID: 36052684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients.
    Volpe M; de la Sierra A; Kreutz R; Laurent S; Manolis AJ
    High Blood Press Cardiovasc Prev; 2014 Jun; 21(2):137-47. PubMed ID: 24532183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
    Volpe M; Tocci G
    Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.